The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | Emerging therapeutic challenges to treating patients with multiple myeloma
Monika Engelhardt, MD, University Medical Center Freiburg, Freiburg, Germany, provides an overview of the sessions that focused on treatment accessibility and efficacy for patients with multiple myeloma (MM). Dr Engelhardt highlights the introduction of CAR T-cell therapy as a potential replacement to autologous stem cell transplantation (autoSCT), identifying patients with MM that can feasibly achieve long-term remission, and the underrepresentation of ethnic minorities in clinical trials. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
